Sugi Predict

Sugi Predict / Compounds / SCHEMBL6089328

SCHEMBL6089328

SCHEMBL6089328

Oc1cc(O)c2cc(Br)ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.44
▸ NT5E P21589 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ MPO P05164 1/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ ALOX15 P16050 1/20 0.40
▸ RXFP1 Q9HBX9 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ BCHE P06276 2/20 0.39
▸ ACHE P22303 2/20 0.39
▸ GRIN1 Q05586 2/20 0.39
▸ GRIN2A Q12879 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24777192 0.84 MPO (0.41) HTTMPOPIM1MEN1KMT2A
SCHEMBL29923741 0.81 ALDH1A1 (0.55) HTTALDH1A1MPOMEN1KMT2A
SCHEMBL5505645 0.81 BACE1 (0.52) HTTNT5EALDH1A1MPORXFP1
SCHEMBL4966064 0.81 ALDH1A1 (0.55) HTTALDH1A1MPOMEN1KMT2A
SCHEMBL9039085 0.78 ALDH1A1 (0.48) HTTALDH1A1DHODHMEN1KMT2A
SCHEMBL5015458 0.78 RXFP1 (0.57) HTTALDH1A1DHODHMEN1KMT2A
SCHEMBL13990744 0.77 NT5E (0.41) HTTNT5EALDH1A1MPODHODH
SCHEMBL3497221 0.77 RXFP1 (0.62) ALDH1A1DHODHMEN1KMT2AATM
SCHEMBL13990862 0.77 RXFP1 (0.48) HTTALDH1A1MPODHODHMEN1
SCHEMBL4214227 0.77 NT5E (0.69) HTTNT5EALDH1A1MPOMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3793613-B1 IMMUNOCONJUGATES BOLT BIOTHERAPEUTICS INC (US) 2025-01-01 — — EP disclosed
US-20220226492-A1 Immunoconjugates Targeting HER2 BOLT BIOTHERAPEUTICS, INC. (US) 2022-07-21 — — US disclosed
US-20220226491-A1 Immunoconjugates Targeting PD-L1 BOLT BIOTHERAPEUTICS, INC. (US) 2022-07-21 — — US disclosed
US-20220152215-A1 Immunoconjugates Targeting CEA BOLT BIOTHERAPEUTICS, INC. (US) 2022-05-19 — — US disclosed
US-20220152215-A1 Immunoconjugates Targeting CEA BOLT BIOTHERAPEUTICS, INC. (US) 2022-05-19 — — US disclosed
US-20220143012-A1 Macromolecule-Supported TLR Agonists BOLT BIOTHERAPEUTICS, INC. (US) 2022-05-12 — — US disclosed
US-20220143012-A1 Macromolecule-Supported TLR Agonists BOLT BIOTHERAPEUTICS, INC. (US) 2022-05-12 — — US disclosed
US-20210154316-A1 Immunoconjugates BOLT BIOTHERAPEUTICS, INC. (US) 2021-05-27 — — US disclosed
US-20210154316-A1 Immunoconjugates BOLT BIOTHERAPEUTICS, INC. (US) 2021-05-27 — — US disclosed
EP-3793613-A1 IMMUNOCONJUGATES Bolt Biotherapeutics, Inc. (US) 2021-03-24 — — EP disclosed
WO-2015057200-A1 HETEROARYL LINKED QUINOLINYL MODULATORS OF RORϒT JANSSEN PHARMACEUTICA NV (BE) 2015-04-23 — — WO disclosed
US-7153865-B2 N-type calcium channel antagonists for the treatment of pain ASTRAZENECA AB (SE) 2006-12-26 — — US disclosed
US-7060834-B2 N-type calcium channel antagonists for the treatment of pain ASTRAZENECA AB (SE) 2006-06-13 — — US disclosed
US-20050131020-A1 N-type calcium channel antagonists for the treatment of pain ASTRAZENECA AB (SE) 2005-06-16 — — US disclosed
EP-1430030-B1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2005-05-18 — — EP disclosed
US-20040266819-A1 N-type calcium channel antagonists for the treatment of pain ASTRAZENECA AB (SE) 2004-12-30 — — US disclosed
EP-1430030-A1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2004-06-23 — — EP disclosed
EP-1430029-A1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2004-06-23 — — EP disclosed
WO-2003018560-A1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2003-03-06 — — WO disclosed
WO-2003018561-A1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2003-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210154316-A1 Immunoconjugates FCGR3B, FCGR2A, FCGR1A HTT 4697/4885NT5E 51/4885ALDH1A1 816/4885
US-20040266819-A1 N-type calcium channel antagonists for the treatment of pain CACNA1E, CACNA1B, CACNA1G HTT 2591/4885NT5E 615/4885ALDH1A1 3081/4885
US-20220226492-A1 Immunoconjugates Targeting HER2 ERBB2, EGFR, ERBB3 HTT 3336/4885NT5E 696/4885ALDH1A1 2672/4885
US-20050131020-A1 N-type calcium channel antagonists for the treatment of pain CACNA1E, CACNA1B, CACNA1A HTT 2118/4885NT5E 668/4885ALDH1A1 4000/4885
US-20220226491-A1 Immunoconjugates Targeting PD-L1 CD274, PDCD1LG2, PDCD1 HTT 3610/4885NT5E 1354/4885ALDH1A1 389/4885
US-20220152215-A1 Immunoconjugates Targeting CEA CD47, FCGR3B, FCGR1A HTT 4609/4885NT5E 701/4885ALDH1A1 1242/4885
US-20220143012-A1 Macromolecule-Supported TLR Agonists TLR8, TLR7, TLR9 HTT 3993/4885NT5E 982/4885ALDH1A1 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.